ANDOVER, Mass.– MeMed, a leader in host-response diagnostics, has surpassed 100,000 patient tests with its MeMed BV® platform, marking a significant milestone in the company’s efforts to transform how infections are diagnosed and managed globally.
The MeMed BV test, which distinguishes between bacterial and viral infections in just 15 minutes using the body’s immune response, is being increasingly adopted in emergency departments, urgent care centers, and hospitals. Its growing use underscores a broader healthcare shift toward precision diagnostics that improve treatment decisions and reduce unnecessary antibiotic prescriptions.
The 100,000th test was conducted at Physicians Premier’s Parkdale clinic in Corpus Christi, Texas. The milestone was celebrated in a joint event between MeMed and the Physicians Premier network, a group of freestanding emergency rooms that has integrated the diagnostic test into its clinical workflows.
“At Physicians Premier, we are committed to delivering cutting-edge, personalized care,” said CEO Teri Cardenas. “MeMed BV has helped our clinicians make faster, more accurate decisions, ultimately improving outcomes while supporting antibiotic stewardship.”
The test’s increasing adoption highlights its clinical value in real-world settings. By helping physicians quickly determine whether an infection is viral or bacterial, MeMed BV supports targeted treatment and limits overuse of antibiotics—a growing public health concern.
“Crossing the 100,000-patient threshold is a powerful validation of our approach to infection management,” said Dr. Eran Eden, MeMed’s Co-Founder and CEO. “This achievement reflects the growing trust of providers who are committed to diagnostic innovation and better patient care.”
MeMed aims to continue expanding its reach through partnerships with healthcare systems, integration of high-throughput analyzers for acute care, and distribution agreements across the U.S., Europe, and emerging markets. With only a small portion of the potential market tapped, the company expects to accelerate growth and further advance the role of host-response diagnostics in clinical practice.
